CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Rhea-AI Summary

CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.

Company management will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" on Thursday, October 9, 2025, at 8:00 AM ET. The company will also be available for one-on-one meetings with institutional investors during the conference.

News Market Reaction – CRVO

+1.74% 1.9x vol

8 alerts

+1.74% Session close to close

+2.8% Peak Tracked

-6.0% Trough Tracked

$82.63M Market Cap

1.9x Rel. Volume

In the Oct 2 session, CRVO gained 1.74%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.8% during that session. Argus tracked a trough of -6.0% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4^th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025.

Panel Details
Title: “Small Firms Tackling Blockbuster Indications”
Date: Thursday, October 9, 2025
Time: 8:00 AM ET

To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

FAQ

When is CervoMed (CRVO) presenting at the ROTH Healthcare Conference 2025?

CervoMed will participate in a panel discussion on Thursday, October 9, 2025, at 8:00 AM ET at the 4th Annual ROTH Healthcare Opportunities Conference in New York.

What is the focus of CervoMed's panel at the ROTH Healthcare Conference?

CervoMed will participate in a panel titled 'Small Firms Tackling Blockbuster Indications', discussing their approach to developing treatments for age-related neurologic disorders.

How can investors meet with CervoMed management at the ROTH Conference?

Investors can request one-on-one meetings with CervoMed management by contacting their institutional representative at Roth.

What type of company is CervoMed (CRVO)?

CervoMed is a clinical stage company focused on developing treatments for age-related neurologic disorders.